17000685

Source:http://linkedlifedata.com/resource/pubmed/id/17000685

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0031325, umls-concept:C0205179, umls-concept:C0671970, umls-concept:C1516213
pubmed:issue	18
pubmed:dateCreated	2006-9-26
pubmed:abstractText	Germinal gene polymorphisms can explain a part of the interpatient pharmacodynamic variability of anticancer drugs, particularly fluoropyrimidines. Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Dihydrouracil Dehydrogenase (NADP), http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Methylenetetrahydrofolate..., http://linkedlifedata.com/resource/pubmed/chemical/Thymidylate Synthase, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1078-0432
pubmed:author	pubmed-author:CiccoliniJosephJ, pubmed-author:Etienne-GrimaldiMarie-ChristineMC, pubmed-author:FerreroJean-MarcJM, pubmed-author:FoaCyrilC, pubmed-author:FormentoJean-LouisJL, pubmed-author:FrancoualMireilleM, pubmed-author:GinotAurélieA, pubmed-author:LacarelleBrunoB, pubmed-author:LargillierRémyR, pubmed-author:MilanoGérardG, pubmed-author:NamerMoïseM, pubmed-author:NebbiaJean-FrançoisJF, pubmed-author:RenéeNicoleN
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5496-502
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:17000685-Adult, pubmed-meshheading:17000685-Aged, pubmed-meshheading:17000685-Aged, 80 and over, pubmed-meshheading:17000685-Base Sequence, pubmed-meshheading:17000685-Breast Neoplasms, pubmed-meshheading:17000685-Deoxycytidine, pubmed-meshheading:17000685-Dihydrouracil Dehydrogenase (NADP), pubmed-meshheading:17000685-Female, pubmed-meshheading:17000685-Fluorouracil, pubmed-meshheading:17000685-Humans, pubmed-meshheading:17000685-Male, pubmed-meshheading:17000685-Methylenetetrahydrofolate Reductase (NADPH2), pubmed-meshheading:17000685-Middle Aged, pubmed-meshheading:17000685-Models, Biological, pubmed-meshheading:17000685-Molecular Sequence Data, pubmed-meshheading:17000685-Pilot Projects, pubmed-meshheading:17000685-Polymorphism, Genetic, pubmed-meshheading:17000685-Thymidylate Synthase
pubmed:year	2006
pubmed:articleTitle	Pharmacogenetics of capecitabine in advanced breast cancer patients.
pubmed:affiliation	Centre Antoine Lacassagne, Nice, and Pharmacokinetic Unit, La Timone University Hospital, Marseille, France.
pubmed:publicationType	Journal Article